A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

Summary

The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participants who: Are children aged between 6 and less than 12 years old Have had migraine for at least 6 months. Weigh more than 15 kilograms All participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Acute Treatment of Migraine

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

6 to 11 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

September 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites